In this episode, we explore the most effective pharmacologic treatments for fibromyalgia, a complex nociplastic pain syndrome. Dr. Daniel Clauw shares his insights on the top drug classes for managing fibromyalgia and discusses why opioids should be avoided. Could the hyperactive endogenous opioid system in fibromyalgia patients explain the ineffectiveness of opioids? Faculty: Daniel Claw, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CME: Nociplastic Pain Syndromes: Focus on Fibromyalgia Pharmacologic Therapies for Fibromyalgia

In this episode, we explore the use of antipsychotic medication in treating children and adolescents with anorexia nervosa. Can these medications play a role in promoting weight gain and reducing comorbid symptoms? Or do the risks outweigh the potential benefits in this vulnerable population? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: CAP Smart Takes Vol. 15 Antipsychotics in the Treatment of Youth With Anorexia Nervosa

Dr. Daniel Clauw discusses the spectrum of fibromyalgia symptoms and the importance of individualized diagnosis. Exploring central nervous system symptoms and tailored treatment options for accurate diagnosis.

In this episode, we delve into the potential for irreversible sexual dysfunction after SSRI use, based on a large-scale Israeli study. Could a few months or even days of antidepressant treatment lead to permanent erectile issues? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: Quick Take Vol. 55 Risk of Irreversible Post‑SSRI Sexual Dysfunction With Antidepressants

Dr. Brian Miller discusses strategies to manage adverse effects of clozapine, including myocarditis, cardiomyopathy, tachycardia, orthostatic hypotension, and metabolic syndrome. Topics include recognition, monitoring, diagnostic measures, and use of adjunctive medications like topiramate and metformin to improve patient outcomes.

In this episode, we explore relapse prevention strategies for youth with depression and anxiety disorders. Are there effective ways to reduce the risk and prolong the time to relapse? Dr. David Rosenberg discusses the findings of a recent meta-analysis and systematic review on this crucial topic. Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 15 Relapse Prevention Strategies for Depression and Anxiety in Remitted Youth

In this episode, we navigate the complexities of initiating and optimizing clozapine treatment for patients with treatment-resistant schizophrenia. How do you chart the course for successful clozapine therapy while managing side effects and drug interactions? Join us as Dr. Brian Miller shares his expertise and valuable psychopharmacology pearls. Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Clozapine: Management and Challenges Initiating and Optimizing Clozapine

In this episode, we discuss the prevalence of smoking among people with psychosis, based on recent findings from the PATH study. Dr. Oliver Freudenreich shares insights on how clinicians can prioritize smoking cessation in this population. How can we bridge the health outcome disparities faced by our patients with psychosis? Faculty: Oliver Freudenreich, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 55 Tobacco Use, Nicotine Dependence, and Cessation Among Adults with Psychosis

In this episode, we delve into the use of clozapine for treatment-resistant psychosis and mood disorders. When should clinicians consider clozapine, and what do expert guidelines recommend? Dr. Brian Miller guides us through the evidence and best practices for utilizing this powerful but often underused medication. Faculty: Brian Miller, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Clozapine: Management and Challenges Using Clozapine for Treatment-Resistant Psychosis and Mood Disorders

In this episode, we explore the role of lithium in treating pediatric bipolar disorder and conduct disorder. Is lithium a viable option for managing these complex conditions in children and adolescents, or are other medications more effective? Faculty: David Rosenberg, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CMEs: CAP Smart Takes Vol. 14 Use of Lithium in Pediatric Bipolar Disorders and Externalizing Childhood-Related Disorders